Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
|Poll|January 16, 2018
Mini Quiz: Motivational Pharmacotherapy
Motivational interviewing can be very useful for addressing patients' ambivalence about psychopharmacologic issues. Take the quiz and learn more.
Advertisement
Which of the following is NOT true of motivational pharmacotherapy?
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
Check out our pipeline updates from September!
Don't miss out on these CME articles! Test your knowledge here.
A cross-sector ACNP task force calls for shared standards and shared data to move psychiatry beyond trial-and-error prescribing.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Advertisement
Advertisement
Trending on Psychiatric Times
1
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
2
From Side Effect to Target: Rethinking Metabolic Dysfunction in Psychiatry
3
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
4
Hippocampal Generative Processes During Sleep Support Rapid Learning of New Associations
5